MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...
-- Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy -- Reprieve ...
Reprieve Cardiovascular Inc. landed $42 million in its first fundraising round out of stealth to fund development of its acute decompensated heart failure treatment. The series A round will support ...
Hosted on MSN
Reprieve secures $61m for ADHF system trial
Reprieve Cardiovascular has closed an oversubscribed $61m Series B financing round, which was spearheaded by Deerfield Management. The funds aim to accelerate the global FASTR II pivotal trial of the ...
German-American medical device firm, Reprieve Cardiovascular, is eyeing up a pivotal trial with its cardiovascular drainage device after reporting success from a first-in-human study. Results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results